Clinical utility of PET/CT in lymphoma

Carmel G. Cronin; Ronan Swords; Mylene T. Truong; Chitra Viswanathan; Eric Rohren; Francis J. Giles; Michael O'Dwyer; John F. Bruzzi

doi:10.2214/AJR.09.2637

Clinical utility of PET/CT in lymphoma

Carmel G. Cronin, Ronan Swords, Mylene T. Truong, Chitra Viswanathan, Eric Rohren, Francis J. Giles, Michael O'Dwyer, John F. Bruzzi

Research output: Contribution to journal › Review article › peer-review

107 Scopus citations

Abstract

OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options. CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.

Original language	English (US)
Pages (from-to)	W91-W103
Journal	American Journal of Roentgenology
Volume	194
Issue number	1
DOIs	https://doi.org/10.2214/AJR.09.2637
State	Published - Jan 2010
Externally published	Yes

Keywords

Lymphoma
PET/CT

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.2214/AJR.09.2637

Cite this

@article{4bc0f98c6a5f4d2a8245b6a9c80f1f7a,

title = "Clinical utility of PET/CT in lymphoma",

abstract = "OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options. CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.",

keywords = "Lymphoma, PET/CT",

author = "Cronin, {Carmel G.} and Ronan Swords and Truong, {Mylene T.} and Chitra Viswanathan and Eric Rohren and Giles, {Francis J.} and Michael O'Dwyer and Bruzzi, {John F.}",

year = "2010",

month = jan,

doi = "10.2214/AJR.09.2637",

language = "English (US)",

volume = "194",

pages = "W91--W103",

journal = "American Journal of Roentgenology",

issn = "0361-803X",

publisher = "American Roentgen Ray Society",

number = "1",

}

TY - JOUR

T1 - Clinical utility of PET/CT in lymphoma

AU - Cronin, Carmel G.

AU - Swords, Ronan

AU - Truong, Mylene T.

AU - Viswanathan, Chitra

AU - Rohren, Eric

AU - Giles, Francis J.

AU - O'Dwyer, Michael

AU - Bruzzi, John F.

PY - 2010/1

Y1 - 2010/1

N2 - OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options. CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.

AB - OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options. CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment.

KW - Lymphoma

KW - PET/CT

UR - http://www.scopus.com/inward/record.url?scp=74749105067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749105067&partnerID=8YFLogxK

U2 - 10.2214/AJR.09.2637

DO - 10.2214/AJR.09.2637

M3 - Review article

C2 - 20028897

AN - SCOPUS:74749105067

SN - 0361-803X

VL - 194

SP - W91-W103

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

IS - 1

ER -

Clinical utility of PET/CT in lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this